KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Capital Expenditures: 2012-2024

Historic Capital Expenditures for Xenon Pharmaceuticals (XENE) over the last 13 years, with Dec 2024 value amounting to $3.1 million.

  • Xenon Pharmaceuticals' Capital Expenditures fell 52.37% to $281,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 46.67%. This contributed to the annual value of $3.1 million for FY2024, which is 45.26% down from last year.
  • Xenon Pharmaceuticals' Capital Expenditures amounted to $3.1 million in FY2024, which was down 45.26% from $5.6 million recorded in FY2023.
  • Xenon Pharmaceuticals' 5-year Capital Expenditures high stood at $5.6 million for FY2023, and its period low was $2.0 million during FY2021.
  • Over the past 3 years, Xenon Pharmaceuticals' median Capital Expenditures value was $3.1 million (recorded in 2024), while the average stood at $3.9 million.
  • As far as peak fluctuations go, Xenon Pharmaceuticals' Capital Expenditures soared by 112.66% in 2020, and later tumbled by 45.26% in 2024.
  • Yearly analysis of 5 years shows Xenon Pharmaceuticals' Capital Expenditures stood at $2.6 million in 2020, then dropped by 22.26% to $2.0 million in 2021, then surged by 41.17% to $2.9 million in 2022, then spiked by 94.09% to $5.6 million in 2023, then plummeted by 45.26% to $3.1 million in 2024.